An interventional study of Broc Shot Capsules Intervention and Placebo Intervention in Reactive Skin, Blemish-Prone Skin and Hormonally Affected Skin, sponsored by BrocShot Inc. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by BrocShot Inc · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.
Among the 374 studies in Acne Vulgaris with a site in United States, this one is the 214th largest by planned enrollment of the 354 interventional ones that give a count, is one of 8 that started in 2026, is one of 78 with no phase, reaches primary completion later than 15 of the 28 other live ones, and was the 374th registered.
792 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →20 of the 374 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Sagimet Biosciences Inc. · Sites in United States
Ages 12+
Integrative Skin Science and Research · Sites in United States
Ages 9+ · Healthy volunteers
Bausch Health Americas, Inc. · Sites in United States
Ages 9–11
Sanofi Pasteur, a Sanofi Company · Sites in United States
Ages 18–45
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Acne Vulgaris studies recruiting now, 15 (33%) set no upper age limit and 29 (64%) stop at 75 or younger; 20 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 82 · Phase 3 82 · Phase 4 72
First in 2002; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 70 across 674 interventional studies indexed under Acne Vulgaris.
Median enrollment 78 across the 354 interventional studies, 59 across the 19 observational. Of the 323 that completed or were terminated, 189 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
287 of 374 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with BrocShot Inc as lead sponsor.
BrocShot Inc has 1 study filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
10 of the studies in Acne Vulgaris with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863193Phase 3Sagimet Biosciences Inc.Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) | 2027-08 |
| NCT06315166PollogenStudy on Using Radiofrequency to Treat Moderate to Severe Acne | 2026-12 |
| NCT02713607University of California, DavisLipidome and Microbiome Profile of Acne | 2027-01 |
| NCT07946250BrocShot IncA Clinical Trial to Evaluate the Effects of Broc Shot Capsules on Skin Appearance and Comfort in Adults With Reactive, Blemish-Prone, or Hormonally Affected Skin | 2027-01 |
| NCT06989840Sagimet Biosciences Inc.Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne | 2027-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 374 studies in Acne Vulgaris with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled, fully decentralized (remote) clinical trial evaluating the effects of Broc Shot Capsules on skin appearance and comfort in adults with reactive, blemish-prone, or hormonally affected skin. Fifty participants aged 18-65 years will be randomly assigned in a 1:1 ratio to receive either Broc Shot Capsules (active) or matched placebo capsules for 8 weeks.
Participants will take 2 capsules once daily and complete self-reported questionnaires and standardized self-captured skin photographs at Baseline, Week 4, and Week 8 via a secure online study platform. Expert dermatologist grading of photographs will be conducted remotely at each timepoint. The study is designed to substantiate consumer product claims related to visible skin improvement and participant-reported skin comfort, and is not intended to evaluate treatment of any clinical dermatological disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Broc Shot Capsules Intervention
Dietary Supplement: Placebo Intervention
Participants will take 2 capsules once daily, with their first meal of the day, avoiding administration with hot or acidic liquids.
Participants will take 2 capsules once daily, with their first meal of the day, avoiding administration with hot or acidic liquids.
Clinician-Assessed Change in Overall Skin Appearance
Change from Baseline in overall skin appearance graded by a qualified dermatologist reviewing participant-submitted digital photographs using a binary Yes/No improvement scale assessing overall skin health, pigmentation, dryness, brightness, scarring, blemishes, redness, and flaking
Time frame: Baseline to Week 8
Participant-Reported Change in Skin Appearance
Change from Baseline in self-reported skin appearance assessed via a participant-reported skin questionnaire
Time frame: Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Clarity
Change from Baseline in self-reported skin clarity assessed via a participant-reported skin questionnaire
Time frame: Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Calmness
Change from Baseline in self-reported skin calmness assessed via a participant-reported skin questionnaire
Time frame: Baseline, Week 4, and Week 8
Participant-Reported Change in Visible Skin Concerns
Change from Baseline in self-reported visible skin concerns assessed via a participant-reported skin questionnaire
Time frame: Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Texture
Change from Baseline in self-reported skin texture assessed via a participant-reported skin questionnaire
Time frame: Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Luminosity
Change from Baseline in self-reported skin luminosity assessed via a participant-reported skin questionnaire
Time frame: Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Age Appearance
Change from Baseline in self-reported skin age appearance assessed via a participant-reported skin questionnaire
Time frame: Baseline, Week 4, and Week 8
Participant-Reported Change in Itching and Irritation
Change from Baseline in self-reported itching and irritation assessed via a participant-reported skin questionnaire
Time frame: Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Comfort
Change from Baseline in self-reported skin comfort assessed via a participant-reported skin questionnaire
Time frame: Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Confidence
Change from Baseline in self-reported skin confidence assessed via a participant-reported skin questionnaire
Time frame: Baseline, Week 4, and Week 8
Start is estimated for Nov 2026; primary completion for Jan 2027, 2 months later.
Of 62 industry-sponsored interventional studies with no phase under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 19. This study's planned 2 months is below that.
Counting every sponsor, half of 120 studies reached it within 9 months; a quarter within 4 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.